Steven M. Foord
`
`Aston Dene
`Dene Lane
`Aston, Stevenage
`Hertfordshire
`SG2 7ES
`Mobile: 07801 229443
`Work: 01438 880602
`e.mail: steven.m.foord@gmail.com
`
`
`
`
`
`
`Summary
`
`10 year academic career starting with BSc in Physiology, a PhD in Pharmacology, a period of post
`doctoral work on neuropeptides then a MRC Training Fellowship in Molecular Biology. Published
`over 30 papers during this period.
`21year career in the pharmaceutical industry with Glaxo, GlaxoWellcome and GlaxoSmithKline at
`Greenford, Ware, Stevenage and Harlow. Won company awards for the introduction of molecular
`pharmacology and leading a drug discovery project from conception to development respectively.
`Published two of the most cited papers on G protein coupled receptors (GPCRs) of the past 10
`years (both in Nature) and more than 30 other papers plus patents and book chapters.
` Engaged in the application of computer biology to drug discovery. Project initiated included
`GPCR structural biology, ‘The Secretome’ and the ‘Druggable Genome’. The latter was directed at
`GSKs Association Genetics program and its collaboration with the Structural Genomics
`Consortium
` Retired 2008 – subsequent consultancy for Bristows, Heptares and MVM Investment.
`
`Recently
` Consultant for Bristows, LLP, London July-December 2018.
` Consultant for Heptares Therapeutics (2008-2017)
`o Responsible for their collaboration with Bioexcel.
`o Established the Heptares ‘sequence to crystal’ database
`o Heptares ‘STAR’ mutations patent support
` Consultant for Seventure Venture Capital regarding Syngenta Therapeutics 2009
` Consultant for Eisai regarding several small GPCR companies 2007
`
`Previously (Department, Division and Site closed 2007-8)
` Director and Site Head, Computational Biology, GlaxoSmithKline (GSK), Harlow
` Reported to David Searls, Senior Vice President and Head of Computational Biology which
`supported drug discovery functions in Stevenage, Harlow, Philadelphia and North Carolina
` Accountable for the computational biology support for the neurosciences therapeutic division.
`
`External Profile
` Core member of the committee for the International Union of Pharmacology (IUPHAR).
` Referee for Nature, Nature Genetics, BMC & Biochemistry
` Referee for the European Commission and the BBSRC.
` Regularly invited to present at academic and industry oriented conferences. Specialises in the
`application of bioinformatics, genetics and molecular pharmacology to drug discovery.
` External PhD examiner for The University of London and The Rockefeller University, NYC.
`
`GlaxoSmithKline 2000-2007
` Accountable for the bioinformatics support of neuroscience, respiratory and inflammation
`therapeutic areas. This involved significant staff management and the large scale analysis of
`microarray expression, proteomics, orthology and genetic association data.
` Responsible for the progressive placement of these resources in the public domain through
`initiatives associated with the European Bioinformatics Institute (Druggability Portal) and the
`European Union (Innovative Medicines Initiative).
` Coordinated the mining of the human genome for pharmaceutically relevant targets and the
`consolidation and organisation of that data into the GSK ‘gene index’. Managed the content of this
`
`EX2055
`Eli Lilly & Co. v. Teva Pharms. Int'l GMBH
`IPR2018-01426
`
`1
`
`

`

`index such that it remained GSKs most used BioInformatics database (in terms of diversity and
`intensity) for eight years.
` Core member of the GSK GPCR targets committee. Successfully wrote grant applications enabling
`six different post doctoral students to work at GSK on aspects of GPCR pharmacology, structural
`biology and informatics.
`
`
`
`
`GlaxoWellcome, Stevenage, 1997-2000
` Gold Award resulting from the initiation and leadership of the Prostaglandin Receptor Research
`Program. Programs are now in the portfolio of Convergence Therapeutics after progression to
`Phase II within GSK
`International responsibility for the identification, mining, data management and progression of
`new GPCR targets. Enabled the identification, cloning & characterisation of the GPCRs for
`GABA, Nicotinic and Carboxylic Acids. I am a named inventor on several patents deriving from
`this work.
` Core member of the GlaxoWellcome BioInfomatics Management committee
` Chair of the Incyte/GW Research Committee, leader of the negotiating and evaluation team and
`responsible for audit and compliance. This was GWs largest collaborative venture within the
`Bioinformatics area.
`
`
`Glaxo Group Research , Ware, 1993-1997
` GGR Head of Research Award for Leadership in Molecular Pharmacology.
` Project Leader for CGRP receptor research leading to the successful identification of the Receptor
`Activity Modifying Proteins (RAMPs) and the successful de novo cloning of the CGRP,
`adrenomedullin and amylin receptors. Lead author on the resulting article in Nature.
`
`
`Glaxo Group Research, Greenford, 1988-1993
` Built and validated the screens for angiotensin, CCK and beta3 adrenoreceptors, the first
`recombinant screens to be run for GPCRs at Glaxo.
`
`Introduced Xenopus oocyte expression and electrophysiology into Glaxo as an experimental tool.
` Purified and characterised the HIV TAT protein demonstrating that its action was via direct
`binding to specific RNA sequences transcribed from the HIV genome.
`
`
`
`1985-1988 MRC Training Fellow, Medical Molecular Biology Unit, Middlesex Hospital Medical
`School. Supervisor: Professor R.K.Craig
`The laboratory pioneered the use of molecular techniques in the U.K. and co-discovered CGRP. In
`collaboration with Celltech we characterised the CGRP gene, its receptor and pharmacology. Winner of
`the Ogden prize in 1987, awarded annually for the best publication from University College, London.
`
`1978-1985 PhD and Post Doctoral Research at University of Newcastle upon Tyne and the
`University of Wales College of Medicine. Luccock Research Scholar. Supervisor: Professor R.
`Hall. PhD awarded for ‘The role of catecholamines in the control of TSH secretion’. I also spent a year
`on post doctoral studies directed at a characterisation of neuropeptides secreted by cultures of foetal rat
`brain.
`
`Education:
`BSc (Hons) 2(i) Physiology, University of Newcastle upon Tyne, 1978
`4 ‘A’ levels, 11 ‘O’levels, South Hunsley Comprehensive School, Near Kingston upon Hull
`
`
`
`
`
`
`
`
`
`
`
`
`
`2
`
`2
`
`

`

`Selected Publications and Presentations
`Over 60 peer-reviewed publications in significant scientific journals, written three book chapters,
`edited an issue of a journal and have made many presentations at international meetings as an invited
`speaker. My work continues to be highly cited.
`
`Selected Invited Presentations at Learned Societies:
`2008 Biochemical Society / Royal Society of Chemistry, London
`2006 7th International Congress of Pharmacology, Beijing
`2005 Society for Experimental Biology, Barcelona
`2004 Wenner Gren Symposium on Receptor Behaviour, Stockholm
`2004 Department of Trade and Industry Satellite Symposium to ISMB, Glasgow
`2003 Alfred Nobel Symposium at the Karolinska Institute, Stockholm
`2002 6th International Congress of Pharmacology, San Francisco
`2001 Molecular Pharmacology Gordon Conference, Ventura
`2000 2nd International Conference on Adrenomedullin and PAMP, Miyazaki, Japan
`2000 Current Concepts in Asthma and Respiratory Research, London
`1999 ASBMB & ASPET Joint Meeting, Boston
`1999 Advances in Receptor Regulation, New York Academy of Science, NY
`1999 Hormone Action, Gordon Research Conference, Meridien, NH
`
`Publications
`I have over 60 peer-reviewed publications in significant scientific journals, written three book chapters,
`edited a journal and held several patents. In Biochemistry/Pharmacology a ‘citation classic’ is generally
`considered a publication cited more than 400 times. Seven qualify.
`2055 Nature 393: 333-339 (1998) Discovery of RAMPs
`1259 Nature 396: 679-682 (1998) Nature of the GABA B receptor
`1255 J Biol Chem. 2003 278:11312-9. Discovery of carboxylic acid receptors
`763 Pharmacol Rev. 2002 54: 233-46. Review of the Calcitonin family of hormones & receptors
`533 Pharmacol Rev. 2005 Jun;57(2):279-88. Definitive list of GPCRs in the human genome
`523 J Biol Chem. 2003 Mar 14;278(11):9869-74. Discovery of nicotinic acid receptors
`433 Mol Pharmacol 56:235-42 (1999) Discovery of amylin receptors
`
`
`3
`
`3
`
`

`

`Peer Reviewed
`
`
`
`
`
`
`
`*
`
`
`
`
`
`
`
`Definition of the G protein-coupled receptor transmembrane
`bundle binding pocket and calculation of receptor similarities for
`drug design.
`Gloriam DE, Foord SM, Blaney FE, Garland SL.
`J Med Chem. 2009 Jul 23;52(14):4429-42.
`
`The G protein-coupled receptor subset of the dog genome is
`more similar to that in humans than rodents.
`Haitina T, Fredriksson R, Foord SM, Schiöth HB, Gloriam DE.
`BMC Genomics. 2009 Jan 15;10:24.
`
`The role of positive selection in determining the molecular
`cause of species differences in disease.
`Vamathevan JJ, Hasan S, Emes RD, Amrine-Madsen H,
`Rajagopalan D, Topp SD, Kumar V, Word M, Simmons MD,
`Foord SM, Sanseau P, Yang Z, Holbrook JD.
`BMC Evol Biol. 2008 Oct 6;8:273.
`
`Important amino acids for the function of the human MT1
`melatonin receptor.
`Kokkola T, Foord SM, Watson MA, Vakkuri O, Laitinen JT.
`Biochem Pharmacol. 2003 May 1;65(9):1463-71.
`
`Molecular identification of high and low affinity receptors for
`nicotinic acid.
`Wise A, Foord SM, Fraser NJ, Barnes AA, Elshourbagy N, Eilert
`M, Ignar DM, Murdock PR, Steplewski K, Green A, Brown AJ,
`Dowell SJ, Szekeres PG, Hassall DG, Marshall FH, Wilson S,
`Pike NB.
`J Biol Chem. 2003 Mar 14;278(11):9869-74.
`
`The Orphan G protein-coupled receptors GPR41 and GPR43
`are activated by propionate and other short chain carboxylic
`acids.
`Brown AJ, Goldsworthy SM, Barnes AA, Eilert MM, Tcheang L,
`Daniels D, Muir AI, Wigglesworth MJ, Kinghorn I, Fraser NJ,
`Pike NB, Strum JC, Steplewski KM, Murdock PR, Holder JC,
`Marshall FH, Szekeres PG, Wilson S, Ignar DM, Foord SM,
`Wise A, Dowell SJ.
`J Biol Chem. 2003 Mar 28;278(13):11312-9.
`
`4
`
`4
`
`

`

`
`
`
`
`
`
`
`
`
`
`
`
`Agonist-promoted internalization of a ternary complex between
`calcitonin receptor-like receptor, receptor activity-modifying
`protein 1 (RAMP1), and beta-arrestin.
`Hilairet S, Bélanger C, Bertrand J, Laperrière A, Foord SM,
`Bouvier M.
`J Biol Chem. 2001 Nov 9;276(45):42182-90.
`
`Protein-protein interaction and not glycosylation determines the
`binding selectivity of heterodimers between the calcitonin
`receptor-like receptor and the receptor activity-modifying
`proteins.
`Hilairet S, Foord SM, Marshall FH, Bouvier M.
`J Biol Chem. 2001 Aug 3;276(31):29575-81.
`
`Pharmacological characterization of receptor-activity-modifying
`proteins (RAMPs) and the human calcitonin receptor.
`Armour SL, Foord S, Kenakin T, Chen WJ.
`J Pharmacol Toxicol Methods. 1999 Dec;42(4):217-24.
`
`Amylin receptor phenotypes derived from human calcitonin
`receptor/RAMP coexpression exhibit pharmacological
`differences dependent on receptor isoform and host cell
`environment.
`Tilakaratne N, Christopoulos G, Zumpe ET, Foord SM, Sexton
`PM.
`J Pharmacol Exp Ther. 2000 Jul;294(1):61-72.
`
`Multiple ramp domains are required for generation of amylin
`receptor phenotype from the calcitonin receptor gene product.
`Zumpe ET, Tilakaratne N, Fraser NJ, Christopoulos G, Foord
`SM, Sexton PM.
`Biochem Biophys Res Commun. 2000 Jan 7;267(1):368-72.
`
`Multiple amylin receptors arise from receptor activity-modifying
`protein interaction with the calcitonin receptor gene product.
`Christopoulos G, Perry KJ, Morfis M, Tilakaratne N, Gao Y,
`Fraser NJ, Main MJ, Foord SM, Sexton PM.
`Mol Pharmacol. 1999 Jul;56(1):235-42.
`
`
`
`
`
`
`
`5
`
`5
`
`

`

`The amino terminus of receptor activity modifying proteins is a
`critical determinant of glycosylation state and ligand binding of
`calcitonin receptor-like receptor.
`Fraser NJ, Wise A, Brown J, McLatchie LM, Main MJ, Foord
`SM.
`Mol Pharmacol. 1999 Jun;55(6):1054-9.
`
`Receptor activity modifying proteins regulate the activity of a
`calcitonin gene-related peptide receptor in rabbit aortic
`endothelial cells.
`Muff R, Leuthäuser K, Bühlmann N, Foord SM, Fischer JA,
`Born W.
`FEBS Lett. 1998 Dec 28;441(3):366-8.
`
`The CGRP receptor can couple via pertussis toxin sensitive and
`insensitive G proteins.
`Main MJ, Brown J, Brown S, Fraser NJ, Foord SM.
`FEBS Lett. 1998 Dec 11;441(1):6-10.
`
`Heterodimerization is required for the formation of a functional
`GABA(B) receptor.
`White JH, Wise A, Main MJ, Green A, Fraser NJ, Disney GH,
`Barnes AA, Emson P, Foord SM, Marshall FH.
`Nature. 1998 Dec 17;396(6712):679-82.
`
`Mutagenesis of human Mel1a melatonin receptor expressed in
`yeast reveals domains important for receptor function.
`Kokkola T, Watson MA, White J, Dowell S, Foord SM, Laitinen
`JT.
`Biochem Biophys Res Commun. 1998 Aug 19;249(2):531-6.
`
`GR196429: a nonindolic agonist at high-affinity melatonin
`receptors.
`Beresford IJ, Browning C, Starkey SJ, Brown J, Foord SM,
`Coughlan J, North PC, Dubocovich ML, Hagan RM.
`J Pharmacol Exp Ther. 1998 Jun;285(3):1239-45.
`
`RAMPs regulate the transport and ligand specificity of the
`calcitonin-receptor-like receptor.
`McLatchie LM, Fraser NJ, Main MJ, Wise A, Brown J,
`Thompson N, Solari R, Lee MG, Foord SM.
`Nature. 1998 May 28;393(6683):333-9.
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`6
`
`6
`
`

`

`Characterization of [3H]-prostaglandin E2 binding to
`prostaglandin EP4 receptors expressed with Semliki Forest
`virus.
`Marshall FH, Patel K, Lundstrom K, Camacho J, Foord SM, Lee
`MG.
`Br J Pharmacol. 1997 Aug;121(8):1673-8.
`
`The structure of the prostaglandin EP4 receptor gene and
`related pseudogenes.
`Foord SM, Marks B, Stolz M, Bufflier E, Fraser NJ, Lee MG.
`Genomics. 1996 Jul 1;35(1):182-8.
`
`Cloning and characterisation of the human 5-HT5A serotonin
`receptor.
`Rees S, den Daas I, Foord S, Goodson S, Bull D, Kilpatrick G,
`Lee M.
`FEBS Lett. 1994 Dec 5;355(3):242-6.
`
`Isolation and characterisation of a human calcitonin-gene-
`related-peptide receptor.
`Foord SM, Craig RK.
`Eur J Biochem. 1987 Dec 30;170(1-2):373-9.
`
`Expression and function of the human calcitonin/alpha-CGRP
`gene in health and disease.
`Craig RK, Riley JH, Edbrooke MR, Broad PM, Foord SM, Al-
`Kazwini SJ, Holman JJ, Marshall I.
`Biochem Soc Symp. 1986;52:91-105.
`
`The role of calcium and calmodulin in mediating release of
`thyrotrophin-releasing hormone by cultured hypothalamic cells.
`Lewis MD, Foord SM, Scanlon MF.
`J Endocrinol. 1987 Nov;115(2):255-62.
`
`Thyrotropin regulates thyrotroph responsiveness to dopamine in
`vitro.
`Foord SM, Peters JR, Dieguez C, Shewring G, Hall R, Scanlon
`MF.
`Endocrinology. 1986 Apr;118(4):1319-26.
`
`Growth hormone responses to growth hormone-releasing factor
`(1-29) in euthyroid, hypothyroid and hyperthyroid rats.
`Dieguez C, Jordan V, Harris P, Foord S, Rodriguez-Arnao MD,
`Gomez-Pan A, Hall R, Scanlon MF.
`J Endocrinol. 1986 Apr;109(1):53-6.
`
`
`
`
`
`*
`
`
`
`*
`
`
`
`
`
`7
`
`7
`
`

`

`Differential production of SRIF 14 and 28 by fetal rat
`hypothalamic cells enriched by velocity sedimentation.
`Lewis MD, Foord SM, Lewis MB, Hall R, Scanlon MF.
`Neuroendocrinology. 1986;44(1):125-31.
`
`Characterization and partial purification of the sodium-
`potassium-ATPase inhibitor released from cultured rat
`hypothalamic cells.
`Morgan K, Lewis MD, Spurlock G, Collins PA, Foord SM,
`Southgate K, Scanlon MF, Mir MA.
`J Biol Chem. 1985 Nov 5;260(25):13595-600.
`
`Lack of effect of the TRH related dipeptide histidyl-proline
`diketopiperazine on TSH and PRL secretion in normal subjects,
`in patients with microprolactinomas and in primary
`hypothyroidism.
`Peters J, Foord S, Dieguez C, Salvador J, Hall R, Scanlon MF.
`Clin Endocrinol (Oxf). 1985 Sep;23(3):289-93.
`
`The influence of oestrogens on the sensitivity of PRL, TSH and
`LH to the inhibitory actions of dopamine in hyperprolactinaemic
`patients.
`Valcavi R, Harris PE, Foord SM, Dieguez C, Evans PJ, Peters
`JR, Hall R, Scanlon MF.
`Clin Endocrinol (Oxf). 1985 Aug;23(2):139-46.
`
`Alpha 1-adrenoreceptors and alpha 1-adrenoreceptor-mediated
`thyrotropin release in cultures of euthyroid and hypothyroid rat
`anterior pituitary cells.
`Dieguez C, Foord SM, Peters JR, Hall R, Scanlon MF.
`Endocrinology. 1985 Aug;117(2):624-30.
`
`The effects of cholinergic blockade on the growth hormone and
`prolactin response to insulin hypoglycaemia.
`Evans PJ, Dieguez C, Foord S, Peters JR, Hall R, Scanlon MF.
`Clin Endocrinol (Oxf). 1985 Jun;22(6):733-7.
`
`Differential effects of acute DA receptor blockade with
`domperidone on LH and TSH release in patients with
`hyperprolactinemia.
`Peters JR, Rodriguez-Arnao MD, Foord SM, Edwards C,
`Dieguez C, Woodhead S, Hall R, Scanlon MF.
`J Endocrinol Invest. 1985 Apr;8(2):163-6.
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`8
`
`8
`
`

`

`Relationships between the circadian rhythms of TSH, prolactin
`and cortisol in surgically treated microprolactinoma patients.
`Salvador J, Wilson DW, Harris PE, Peters JR, Edwards C,
`Foord SM, Dieguez C, Hall R, Scanlon MF.
`Clin Endocrinol (Oxf). 1985 Mar;22(3):265-72.
`
`The effects of thyroid hormone deprivation in vivo and in vitro
`on growth hormone (GH) responses to human pancreatic
`(tumor) GH-releasing factor (1-40) by dispersed rat anterior
`pituitary cells.
`Dieguez C, Foord SM, Peters JR, Hall R, Scanlon MF.
`Endocrinology. 1985 Mar;116(3):1066-70.
`
`Release of an active sodium transport inhibitor (ASTI) from rat
`hypothalamic cells in culture.
`Morgan K, Foord SM, Spurlock G, Charalambous BM, Dieguez
`C, Scanlon MF, Mir MA.
`Endocrinology. 1984 Oct;115(4):1642-4.
`
`Rat anterior pituitary cells maintained on artificial capillaries:
`responses of thyrotrophs and lactotrophs to depolarization, TRH
`and dopamine.
`Dieguez C, Foord SM, Newman GR, Shewring G, Hall R,
`Jackson IM, Peters JR, Scanlon MF.
`Mol Cell Endocrinol. 1984 Aug;37(1):73-82.
`
`Hypothyroid pituitary cells in culture: an analysis of thyrotropin
`and prolactin responses to dopamine (DA) and DA receptor
`binding.
`Foord SM, Peters JR, Dieguez C, Jasani B, Hall R, Scanlon
`MF.
`Endocrinology. 1984 Jul;115(1):407-15.
`
`The effects of long term growth hormone releasing factor (GRF
`1-40) administration on growth hormone secretion and
`synthesis in vitro.
`Dieguez C, Foord SM, Shewring G, Edwards CA, Heyburn PJ,
`Peters JR, Hall R, Scanlon MF.
`Biochem Biophys Res Commun. 1984 May 31;121(1):111-7.
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`9
`
`9
`
`

`

`Interactions among epinephrine, thyrotropin (TSH)-releasing
`hormone, dopamine, and somatostatin in the control of TSH
`secretion in vitro.
`Dieguez C, Foord SM, Peters JR, Hall R, Scanlon MF.
`Endocrinology. 1984 Mar;114(3):957-61.
`
`Exaggerated circadian variation in basal thyrotropin (TSH) and
`in the dopaminergic inhibition of TSH release in pathological
`hyperprolactinemia: evidence against a hypothalamic
`dopaminergic defect.
`Rodriguez-Arnao MD, Peters JR, Foord SM, Dieguez C,
`Edwards C, Gomez-Pan A, Hall R, Newcombe RG, Scanlon
`MF.
`J Clin Endocrinol Metab. 1983 Nov;57(5):975-80.
`
`[Current problems in the differential diagnosis of
`hyperprolactinemia].
`Salvador J, Rodríguez-Arnao MD, Diéguez C, Foord S, Peters
`J, Scanlon MF, Moncada E, Gómez-Pan A, Hall R.
`Rev Med Univ Navarra. 1983 Sep;27(3):11-8.
`
`Alpha 1-adrenoreceptors on intact rat anterior pituitary cells:
`correlation with adrenergic stimulation of thyrotropin secretion.
`Peters JR, Foord SM, Dieguez C, Scanlon MF, Hall R.
`Endocrinology. 1983 Jul;113(1):133-40.
`
`Dopamine receptors on intact anterior pituitary cells in culture:
`functional association with the inhibition of prolactin and
`thyrotropin.
`Foord SM, Peters JR, Dieguez C, Scanlon MF, Hall R.
`Endocrinology. 1983 May;112(5):1567-77.
`
`The influence of cyclosporin a on experimental autoimmune
`thyroid disease in the rat.
`McGregor AM, Rennie DP, Weetman AP, Hassman RA, Foord
`SM, Dieguez C, Hall R.
`Life Sci. 1983 Jan 3-10;32(1-2):97-108.
`
`The influence of methimazole on thyroglobulin-induced
`autoimmune thyroiditis in the rat.
`Rennie DP, McGregor AM, Keast D, Weetman AP, Foord SM,
`Dieguez C, Williams ED, Hall R.
`Endocrinology. 1983 Jan;112(1):326-30.
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`10
`
`10
`
`

`

`Dopaminergic control of TSH secretion in isolated rat pituitary
`cells.
`Foord SM, Peters J, Scanlon MF, Rees Smith B, Hall R.
`FEBS Lett. 1980 Dec 1;121(2):257-9.
`
`Dopaminergic inhibition of thyrotropin secretion.
`Foord SM, Scanlon MF, Smith BR, Hall R.
`Biochem Soc Trans. 1980 Oct;8(5):605.
`
`
`
`
`
`
`
`
`11
`
`11
`
`

`

`Reviews
`
`Heterodimerization of the GABAB receptor-implications for GPCR
`signaling and drug discovery.
`Marshall FH, Foord SM.
`Adv Pharmacol. 2010;58:63-91.
`
`Lowering industry firewalls: pre-competitive informatics initiatives
`in drug discovery.
`Barnes MR, Harland L, Foord SM, Hall MD, Dix I, Thomas S,
`Williams-Jones BI, Brouwer CR.
`Nat Rev Drug Discov. 2009 Sep;8(9):701-8.
`
`International Union of Pharmacology. LXXII. Recommendations for
`trace amine receptor nomenclature.
`Maguire JJ, Parker WA, Foord SM, Bonner TI, Neubig RR,
`Davenport AP.
`Pharmacol Rev. 2009 Mar;61(1):1-8.
`
`
`
`
`
`IUPHAR-DB: the IUPHAR database of G protein-coupled
`receptors and ion channels.
`Harmar AJ et al.
`Nucleic Acids Res. 2009 Jan;37(Database issue):D680-5.
`
`Drug discovery in the extracellular matrix.
`Huxley-Jones J, Foord SM, Barnes MR.
`Drug Discov Today. 2008 Aug;13(15-16):685-94.
`
`International Union of Pharmacology. LVI. Ghrelin receptor
`nomenclature, distribution, and function.
`Davenport AP, Bonner TI, Foord SM, Harmar AJ, Neubig RR, Pin
`JP, Spedding M, Kojima M, Kangawa K.
`Pharmacol Rev. 2005 Dec;57(4):541-6.
`
`New methods for researching accessory proteins.
`Foord SM, Topp SD, Abramo M, Holbrook JD.
`J Mol Neurosci. 2005;26(2-3):265-76.
`
`International Union of Pharmacology. XLVI. G protein-coupled
`receptor list.
`Foord SM, Bonner TI, Neubig RR, Rosser EM, Pin JP, Davenport
`AP, Spedding M, Harmar AJ.
`Pharmacol Rev. 2005 Jun;57(2):279-88.
`
`
`
`12
`
`12
`
`

`

`Current status of drug receptor nomenclature: receptor closure?
`The role of NC-IUPHAR.
`Spedding M, Foord SM, Hofmann F.
`Expert Opin Investig Drugs. 2004 May;13(5):461-4.
`
`Matching accessories.
`Foord SM.
`Sci STKE. 2003 Jul 8;2003(190):pe25.
`
`Receptor classification: post genome.
`Foord SM.
`Curr Opin Pharmacol. 2002 Oct;2(5):561-6.
`
`Bioinformatics and type II G-protein-coupled receptors.
`Foord SM, Jupe S, Holbrook J.
`Biochem Soc Trans. 2002 Aug;30(4):473-9.
`
`International Union of Pharmacology. XXXII. The mammalian
`calcitonin gene-related peptides, adrenomedullin, amylin, and
`calcitonin receptors.
`Poyner DR, Sexton PM, Marshall I, Smith DM, Quirion R, Born W,
`Muff R, Fischer JA, Foord SM.
`Pharmacol Rev. 2002 Jun;54(2):233-46.
`
`Transgenic gene knock-outs: functional genomics and therapeutic
`target selection.
`Harris S, Foord SM.
`Pharmacogenomics. 2000 Nov;1(4):433-43.
`
`The N-terminus of RAMPs is a critical determinant of the
`glycosylation state and ligand binding of calcitonin receptor-like
`receptor.
`Foord SM, Wise A, Brown J, Main MJ, Fraser NJ.
`Biochem Soc Trans. 1999 Aug;27(4):535-9.
`
`RAMPs: accessory proteins for seven transmembrane domain
`receptors.
`Foord SM, Marshall FH.
`Trends Pharmacol Sci. 1999 May;20(5):184-7.
`
`TSH neuroregulation and alterations in disease states.
`Peters JR, Foord SM, Dieguez C, Scanlon MF.
`Clin Endocrinol Metab. 1983 Nov;12(3):669-94.
`
`
`
`13
`
`13
`
`